--- title: "Short Interest in Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Decreases By 54.9%" type: "News" locale: "en" url: "https://longbridge.com/en/news/295994399.md" description: "Short interest in Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) dropped 54.9% to 28,818 shares as of July 31st. The stock opened at $21.55 with a market cap of $70.93 billion. Recent quarterly earnings showed $0.22 EPS and $2.14 billion revenue. Analyst ratings include upgrades from Goldman Sachs and Zacks, alongside a downgrade from UBS, resulting in an average 'Moderate Buy' rating." datetime: "2026-08-15T07:20:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295994399.md) - [en](https://longbridge.com/en/news/295994399.md) - [zh-HK](https://longbridge.com/zh-HK/news/295994399.md) generator: "portal-rs" --- # Short Interest in Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Decreases By 54.9% Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) was the target of a large drop in short interest in the month of July. As of July 31st, there was short interest totaling 28,818 shares, a drop of 54.9% from the July 15th total of 63,921 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 465,929 shares, the days-to-cover ratio is presently 0.1 days. Get **Chugai Pharmaceutical** alerts: ## Chugai Pharmaceutical Price Performance CHGCY stock opened at $21.55 on Friday. The firm has a market cap of $70.93 billion, a price-to-earnings ratio of 23.42 and a beta of 0.60. Chugai Pharmaceutical has a 1-year low of $20.27 and a 1-year high of $34.84. The firm has a fifty day moving average price of $22.57 and a two-hundred day moving average price of $25.87. Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last posted its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.71%. The company had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. As a group, analysts expect that Chugai Pharmaceutical will post 0.96 EPS for the current fiscal year. ## Wall Street Analyst Weigh In A number of research firms have recently issued reports on CHGCY. The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Monday, June 15th. Zacks Research upgraded Chugai Pharmaceutical to a "hold" rating in a research report on Friday, May 29th. Finally, UBS Group lowered Chugai Pharmaceutical from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy". **Read Our Latest Stock Report on Chugai Pharmaceutical** ## About Chugai Pharmaceutical (Get Free Report) Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai's activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support. Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics. ## Recommended Stories - Five stocks we like better than Chugai Pharmaceutical - Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors - Quantum Leaps: Debt-Free as AI Storage Demand Accelerates - NVIDIA's $500 Billion GPU Financing Deal Fuels Path Toward $270 - Sandisk’s Margins Look Like Software. Can They Last? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Chugai Pharmaceutical Right Now? Before you consider Chugai Pharmaceutical, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list. While Chugai Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [CHGCY.US](https://longbridge.com/en/quote/CHGCY.US.md) - [4519.JP](https://longbridge.com/en/quote/4519.JP.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [UBS.US](https://longbridge.com/en/quote/UBS.US.md) - [SONY.US](https://longbridge.com/en/quote/SONY.US.md) - [6758.JP](https://longbridge.com/en/quote/6758.JP.md) - [TSM.US](https://longbridge.com/en/quote/TSM.US.md) - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [SNDK.US](https://longbridge.com/en/quote/SNDK.US.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) ## Related News & Research - [Chugai files Japan approval bid for vamikibart in non-infectious uveitic macular edema](https://longbridge.com/en/news/296868472.md) - [Chugai files Japan application for Tecentriq as adjuvant MSI-high colon cancer treatment](https://longbridge.com/en/news/295890880.md) - [Zhihu ADR GAAP EPADS of -$0.07, revenue of $101.7M misses by $3.39M](https://longbridge.com/en/news/297015296.md) - [Wuxi Biologics ADR Non-GAAP EPS of RMB0.81, revenue of RMB11.78B](https://longbridge.com/en/news/296950743.md) - [Chugai licenses anti-dengue antibody AID351 to GSK in exclusive deal](https://longbridge.com/en/news/296167792.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**